Limerick BioPharma Inc. Names Jill Carroll to Serve as Vice President of Strategic Corporate Development

SOUTH SAN FRANCISCO, Calif.—August 17, 2010—Limerick BioPharma, Inc., a developer of innovative therapies that help cells pump unwanted or toxic substances away from vulnerable tissues, has announced that Jill Carroll has joined the firm as Vice President of Strategic Corporate Development.

Ms. Carroll comes to Limerick from Berkeley, California-based Dynavax Technologies where she was responsible for corporate development and strategic planning. At Dynavax she helped forge and foster strategic partnerships with leading pharmaceutical companies including GSK, Merck, AstraZeneca and Novartis. She was also actively involved in substantial private and public financings. Before joining Dynavex Ms. Carroll was a consultant specializing in biotech partnering and commercial development at Clearview Projects, and focused on serving the pharmaceutical & health care industries at Mercer Management Consulting.

“We’re excited to welcome Jill to the Limerick team,” said Wendye Robbins, MD, President and CEO. “She brings an important skill set and professional vision that will help support our long-term success.”

Ms. Carroll received her M.S. in Biochemistry, Cellular & Molecular Biology from Johns Hopkins University and her B.S. in Chemistry from Duke University.

About Limerick BioPharma

Limerick BioPharma (http://www.limerickbio.com) is developing small molecule modulators of cell membrane-bound transporters to rid cells of unwanted toxins. By activating cellular transport pumps to redistribute drugs away from organs and tissues where they have adverse effects, the Company’s proprietary compounds minimize toxic side effects at non-targeted vulnerable organs and tissues while maintaining or enhancing a drug’s desired effects. In the monotherapy setting, Limerick is developing compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia via a novel mechanism related to reverse cholesterol transport.

Natalie Bouaravong Feinstein Kean Healthcare an Ogilvy PR Worldwide Company 111 Sutter Street, 11th Floor San Francisco, CA 94104 T 415-677-2746 F 415-677-2720

MORE ON THIS TOPIC